Establishing Sandoz as a Global Pioneer in Patient Access
Summary of work
Despite their established benefits, value medicines, such as biosimilars and generics are regularly undervalued and underused by healthcare systems and physicians, largely due to insufficient policy incentives, lack of biosimilar competition, low awareness and misconceptions around being less safe, efficacious, and innovative that branded medicines.
As the manufacturer of the world’s first approved biosimilar, Sandoz sought to establish itself as a leader in championing the value of these medicines and reducing barriers to drive greater patient access to medicines and support the financial sustainability of healthcare systems.
Porter Novelli and Sandoz used a great strategy of leading conversations in patient access by being part of the conversation. The visibility of senior executives also gives a very strong endorsement of their position. With an understandable and admirable goal they achieved a credible impact on the patient community.